P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

Genzyme Molecular Oncology: On the way to perfecting Technologies

NDReg1

Date: 20 Mar 2008
Time: 19:36:02

Comments

http://www.streetblowjobs.com/main.htm?id=chikenn http://www.herfirstanalsex.com/?revid=28792 http://www.milflessons.com/t1/revs=milfreg/ http://www.bangboat.com/?revid=28792 http://www.milfnextdoor.com/main.htm?id=chikenn http://www.eurosexparties.com/main.htm?id=chikenn http://www.collegewildparties.com/?revid=28792 http://www.milfhunter.com/main.htm?id=chikenn

Date: 29 Jun 2001
Time: 16:33:34

Comments

Great managements know what they want to do and do it. This statement applies best to Genzyme Molecular Oncology (GZMO).

As its name implies, this firm intends to be “The Cancer Center” developing most promising approaches for the treatment of malignancies. Genzyme Molecular Oncology utilizes its powerful proprietary functional genomics and antigen discovery technology platforms to develop cancer products focused on cancer vaccines and angiogenesis inhibitors and to generate partnering revenue. It is shaping new cancer therapies through the integration of its genomics, gene and cell therapy, small-molecule drug discovery, and protein therapeutic capabilities.

The firm’s strength resides in the scientists vast knowledge about the disciplines involved in various approaches and, most importantly, the problems that haunt each and every procedure. What we really like in this firm is its decision to complement the different technologies with whatever is missing to render them perfect.

Today, GZMO announced that it has acquired an exclusive license to significant patent rights covering the fusion of dendritic cells and tumor cells from BruCells, S.A./N.V. of Brussels, Belgium. This license is a key addition to Genzyme Molecular Oncology's valuable patent portfolio surrounding cell fusion technology.

Dendritic cells are antigen presenting cells and are viewed now as indispensable for the success of cancer treatments, especially those that aim at boosting the immune system’s capability to destroy cancer. Fit best in this category are vaccines, i.e., cancer therapeutic vaccines.

The technology licensed by GZMO was developed by a consortium of investigators at the Universite Libre de Bruxelles (ULB) and the Vrije Universiteit Brussel (VUB) in Belgium. BruCells was subsequently created by the universities and the regional government of Brussels as a for-profit venture dedicated to the development of cell therapies. In connection with the license, Genzyme Molecular Oncology is sponsoring a two-year research program at BruCells related to the fusion technology. Financial terms were not disclosed.

As the president of GZMO said, the firm is committed to creating a broad and tight patent portfolio around our fusion technology vaccines. The man said that "The acquisition of this intellectual property from BruCells is a key addition to our cell fusion portfolio and further strengthens our patent position surrounding this promising technology. We look forward to working with some of the leading experts in the field of dendritic cell therapy through the research program we have just created."

"The research teams at ULB and VUB are pioneers of fusion technology," commented Gilles Capart, president of BruCells. "The collaboration will strengthen the technology platform of BruCells in cell therapy and will accelerate the development of dendritic cell fusion as a promising approach to the treatment of cancer."

. The technology combines a patient's dendritic cells with their inactivated tumor cells using a chemical fusion or an electrofusion procedure. The fused cells are injected back into the patient in order to stimulate an immune response against the patient's cancer. There is no need to identify the appropriate specific antigens to create a tumor vaccine in this case as the fusion vaccine incorporates the entire menu of antigens found on the original tumor to provide the target for the immune system.

Once administered, a cancer vaccine stimulates the immune system to seek out and destroy cancer cells that display the antigens included in the vaccine.

Genzyme Molecular Oncology will save time and money as it will benefit from substantial pre-clinical, clinical and pharmaceutical research on dendritic cells conducted under the leadership of professors Muriel Moser, Michel Goldman and Thierry Velu at ULB and Kris Thielemans at VUB. These professors will be involved as principal investigators in the joint research program sponsored by GZMO.

CELL FUSION TRILAS

Genzyme Molecular Oncology is currently conducting three phase 1-2 cancer vaccine trials in breast cancer, melanoma, and kidney cancer -- using a dendritic/cancer cell fusion technology. These trials are being sponsored by investigators Donald Kufe, M.D., professor of medicine, the Dana- Farber Cancer Institute and Harvard Medical School, David Avigan, M.D., director, bone marrow transplant program at the Beth Israel Deaconess Medical Center and Harvard Medical School, and Jianlin Gong, M.D., instructor of medicine, the Beth Israel Deaconess Medical Center and Harvard Medical School.

ELECTROFUSION TRIALS

The company expects to initiate two additional cancer vaccine trials in the second half of 2001. The first is in melanoma and the second in kidney cancer -- using an electrofusion process. Safety and efficacy data from these five trials will allow Genzyme Molecular Oncology to compare between the cell fusion technology and the electofusion process. in multiple cancer indications.

This press release contains forward-looking statements based on management's current expectations, including statements about the timing of initiation of clinical trials for the fusion technology vaccines. Actual results may materially differ due to numerous factors, including without limitation: the actual results of Genzyme Molecular Oncology's ongoing clinical trials; the timing and content of decisions made by the FDA and other regulatory authorities; the ability to enroll patients in clinical trials; and the risks and uncertainties described in reports filed by Genzyme Corporation with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation Exhibit 99.2 to Genzyme's 2000 Annual Report on Form 10-K. Genzyme Molecular Oncology Division common stock is a series of common stock of Genzyme Corporation. Therefore, holders of Genzyme Molecular Oncology Division common stock are subject to all of the risks and uncertainties described in the aforementioned reports.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName